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Protocol
AbstrACt
Introduction The ‘Use of a Multi-drug Pill in Reducing 
cardiovascular Events’ (UMPIRE) trial was a randomised 
controlled clinical trial evaluating the impact of a 
polypill strategy on adherence to indicated medication 
in a population with established cardiovascular disease 
(CVD) of or at high risk thereof. The aim of Researching 
the UMPIRE Processes for Economic Evaluation in the 
National Health Service (RUPEE NHS) is to estimate the 
potential health economic impact of a polypill strategy for 
CVD prevention within the NHS using UMPIRE trial and 
other relevant data. This paper describes the design of a 
modelled economic evaluation of the impact of increased 
adherence to the polypill versus usual care among the UK 
UMPIRE participants.
Methods and analysis As recommended by the 
International Society for Pharmacoeconomics and 
Outcomes Research and the Society for Medical Decision 
Making modelling guidelines, a review of published CVD 
models was undertaken to identify the most appropriate 
modelling approach and structure. The review was carried 
out in the electronic databases, MEDLINE and EMBASE. 
40 CVD models were identified from 57 studies, the 
majority of economic models were health state transition 
cohort models and individual-level simulation models. The 
findings were discussed with clinical experts to confirm 
the approach and structure. An individual simulation 
approach was identified as the most suitable method to 
capture the heterogeneity in the population at CVD risk. 
RUPEE-NHS will use UMPIRE trial data on adherence to 
estimate the long-term cost-effectiveness of the polypill 
strategy.
Dissemination The evaluation findings will be presented 
in open-access scientific and healthcare policy journals 
and at national and international conferences. We will also 
present findings to NHS policy makers and pharmaceutical 
companies.
IntroDuCtIon
Adherence to recommended preventive 
medication regimes1 2 in people at high risk 
of cardiovascular disease (CVD) is low, even 
in high-income countries.3 Poor adherence 
is associated with greater deterioration in 
health status and increased healthcare costs,4 
and studies have shown that improved adher-
ence to medication is associated with clinical 
benefits.5 CVD preventive medication typi-
cally involves several drugs, and adherence 
is inversely proportional to the number of 
prescriptions. Furthermore, physician inertia 
and patient resistance present barriers to 
initiating or restarting full recommended 
therapy. A single pill that includes several indi-
cated drugs (a ‘polypill’) may improve long-
term adherence by addressing these issues. If 
the polypill is priced lower than the price of 
the pills bought separately, it will also make 
it more affordable.6 7 The UMPIRE (Use of 
a Multi-drug Pill in Reducing cardiovascular 
Events) clinical trial was set up to evaluate 
the polypill in patients with or at high risk of 
CVD.
The UMPIRE trial randomised 2004 partic-
ipants with established CVD (prior CVD event 
such as stroke or myocardial infarction (MI)) 
or at high risk of CVD (defined as a 5-year risk 
of>15%) based in India, England, Ireland and 
the Netherlands to either the polypill or usual 
strengths and limitations of this study
 ► This paper provides a clear outline of how a model 
for an economic evaluation is developed.
 ► Providing an outline of the model structure that 
includes details on the underlying epidemiology and 
data inputs will add transparency to the findings of 
the RUPEE-NHS study.
 ► Though the model has been designed to include all 
major adverse and beneficial effects of treatment, 
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care. The primary outcome of the trial was adherence to 
indicated treatments (statin, aspirin and two blood-pres-
sure-lowering drugs), measured as self-reported current 
use of antiplatelet, statin and ≥2 blood-pressure-low-
ering therapies for at least 4 days in the week preceding 
visits (baseline and end-of-trial visits). Other outcomes 
included systolic blood pressure (SBP) and low-density 
lipoprotein cholesterol (LDL-C). The trial found that the 
use of a polypill strategy resulted in greater adherence to 
treatment at 15 months and significant improvements in 
SBP and LDL-C. Detailed results and a description of the 
UMPIRE trial protocol are available.8 9
UMPIRE collected data on resource use and self-re-
ported health-related quality of life using the EQ-5D. In 
order to estimate the long-term costs and health outcomes 
associated with the polypill strategy, an economic model 
is required. Due to differences in the patient population, 
care pathways and healthcare costs, separate analyses are 
needed for the four participating countries.
The analysis of the UMPIRE English trial data 
(Researching the UMPIRE Processes for Economic Eval-
uation in the National Health Service (RUPEE-NHS)) 
aims to estimate the cost-effectiveness of the polypill 
strategy compared with conventional multi-drug therapy 
for the prevention of  CVD in English NHS patients 
with or at high risk of CVD. The RUPEE (NHS) study 
will use UMPIRE English trial data on adherence to the 
polypill and will develop an economic model to estimate 
cost-effectiveness.
The aim of this paper is to detail the modelling plan for 
the RUPEE (NHS) study.
MethoDs
Model design process
An economic model has been described as a mathemat-
ical framework that represents reality at an adequate 
level of detail to inform clinical or policy decisions.10 
Guidelines on modelling produced by the International 
Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) and the Society for Medical Decision Making 
(SMDM) joint taskforce recommend that it is best prac-
tice to carry out a conceptualisation process prior to 
programming the economic model. This process has two 
distinct components: specification of the study question 
and economic model.11
Specification of the study question
The first component informs choices about how to struc-
ture the economic model and parameters.
The RUPEE (NHS) study aims to evaluate two different 
treatment strategies in a population with or at high risk of 
CVD. The population for the economic model is defined 
by the inclusion criteria of the UMPIRE trial.9 The inclu-
sion criteria are listed below:
 ► Aged ≥18 years and
 ► High CVD risk defined as either established athero-
thrombotic CVD (history of coronary heart disease 
(CHD), ischaemic cerebrovascular disease or periph-
eral arterial disease (PAD)) or a 5-year risk of ≥15% 
calculated using the Framingham risk equation
The economic model will evaluate the polypill strategy 
compared with usual medication. In the UMPIRE trial, 
participants assigned to the polypill received one of two 
versions: version 1 contained 75 mg aspirin, 40 mg simvas-
tatin, 10 mg lisinopril and 50 mg atenolol, and version 2 
contained the same ingredients but substituted 12.5 mg 
hydrochlorothiazide for 50 mg atenolol. Participants 
assigned to usual care continued taking medications as 
prescribed by their general practitioner (GP).
The RUPEE (NHS) study will follow guidelines for 
modelling health technologies as recommended by 
the National Institute for Health and Care Excellence 
(NICE).12 Therefore an NHS and Personal Social 
Services perspective will be adopted to measure health 
service resource use, and health-related quality of life 
will be measured by quality-adjusted life years (QALYs) 
obtained using the EQ-5D. As per the NICE guidelines, 
costs and QALYS will be discounted at a rate of 3.5% 
per year.12 The time horizon reflected in the economic 
model will be lifetime to represent the chronic nature 
of CVD.
Conceptualisation of the economic model
The second component of the conceptualisation 
process involves defining the economic model. There 
are two steps to this approach. The first step is to iden-
tify the appropriate modelling approach. The model-
ling approach defines the analytical framework of the 
economic model. Different types of analytical frame-
works have been used to represent CVD including 
decision trees, state transition models, compartmental 
models, individual simulation models and hybrid 
models, which often combine elements from different 
frameworks.13–17
The second step determines the underlying structure 
of the analytical framework, which will represent the 
disease and care pathway. The modelling approach needs 
to reflect: (1) CVD and the care pathway for this popula-
tion, (2) the beneficial and adverse effects of treatment 
(polypill or usual care) and (3) the impact of increased 
adherence to treatment on health outcomes.
The guidelines produced by ISPOR-SMDM on model-
ling recommend that existing models addressing related 
problems should be reviewed as this approach can help 
identify both the modelling approach and underlying 
structure.11 To inform the RUPEE (NHS) economic 
model, we carried out a review of published models eval-
uating interventions for CVD.
Review of published CVD economic models
The purpose of the literature review was to identify the 
appropriate analytical framework to represent the deci-
sion problem. The literature review also aimed to inform 
the underlying model structure: disease and care pathway.
 o
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Search strategy
The search strategy was conducted using the NHS 
Economic Evaluation Database, the National Institute for 
Health Research Health Technology Assessment mono-
graph series and the NICE guidelines website. The search 
terms used included ‘cardiovascular disease’, ‘coronary 
heart disease’, ‘stroke’, ‘myocardial infarction’, ‘angina’ 
and ‘peripheral artery disease’. Studies were excluded from 
the review if they did not discuss the development or review 
of an economic model, if no disease states for CVD were 
included in the model and if the focus of the study was a 
diagnostic test or surgical intervention where the economic 
model used a time frame of <10 years. Studies were not 
excluded on the basis of intervention (drug treatment or 
lifestyle intervention) or on the basis of date published 
or language. We developed a data extraction form that 
included fields on model purpose, structure, health states 
and events, transparency and validation. We did not collate 
information about the findings of the model as the objective 
of the review was to identify alternative model frameworks 
and methods used to represent CVD.
An initial general literature search identified a 2006 
systematic review of CHD policy models by Unal et al, which 
was updated in 2008 by Capewell et al and expanded to 
include stroke models.17 18 The review by Capewell et al 
identified seven ‘notable’ CHD models (of which six had 
been identified in the previous review by Unal et al), nine 
stroke models and several models that were currently in 
development at the time of publication. We reviewed the 
notable models and models in development identified by 
Capewell et al. Citation searching of both systematic reviews 
was carried out to identify other models published since 
2008.
Review findings
Overall, 57 studies were identified that reported on 40 
CVD models. Figure 1 presents the flowchart for the 
search strategy.
Figure 1 Flow chart for search strategy for cardiovascular disease models. NHS EED, National Health Service Economic 
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The search found several studies that reported on 
the same model; for example, the IMPACT CHD model 
developed by Capewell et al was used in analyses of CVD in 
other populations.19 In some cases, a model was adapted 
for different analyses, such as the Sheffield model, which 
was developed to evaluate statin therapy and was then 
adapted for use in the development of the NICE guide-
lines for lipid modification.1 20 The Sheffield model was 
also partially used in a whole population modelling study 
by Barton et al.13
Further details of the review can be found in 
the online supplementary appendix. The appendix 
includes a list of the reviewed models (see table 1 and 
online supplementary appendix), an example of the 
data extraction form and an example of an illustration 
and details of one of the reviewed models (see figure 1 
and online supplementary appendix). Schematic illus-
trations of several models were used in discussions with 
clinical experts about the different types of modelling 
approaches.
Modelling approach
The search identified that the two most commonly used 
modelling approaches were health state transition cohort 
models and individual-level simulation models. Both 
approaches were critically assessed to determine their 
suitability to capture the disease and care pathway.
A cohort model can be defined as any model that esti-
mates the outcomes for a group of patients, whereas with 
a patient-level simulation, outcomes are evaluated at the 
individual level. Therefore, one of the main differences 
between the two approaches is how they estimate costs 
and QALYs: cohort models estimate expected costs and 
QALYs for the modelled population as a whole, whereas 
individual-level simulation models estimate cost and 
QALYs for each individual and the average is taken across 
the sample.
With a health state transition cohort model, the popu-
lation progresses through a set of mutually exclusive 
health states at regular intervals called cycles, determined 
by a predefined transition matrix. Health state transi-
tion cohort models are also commonly called Markov 
models. However, such models are only Markovian when 
they display the Markovian ‘memoryless’ property where 
the progression of the patient through the model is only 
dependent on the current state in which the patient 
resides and not on anything that happened before they 
entered that health state. It is also possible to model at the 
individual level using a state transition model by sampling 
probabilities for each individual patient to experience a 
particular transition in each model cycle.21
Both model approaches can use a discrete time 
approach: with this approach, the model cycle length will 
be defined in advance. The cohort or individual prog-
ress through health states or events that represent the 
disease pathway, and only one event may occur within 
each cycle length. Costs and QALYs are updated once per 
cycle. Alternatively, individual-level simulation models are 
often set up as discrete event simulations (DESs). With a 
DES approach, an event can occur at any time point; for 
example, an event could occur at 3 months, 1 year and 20 
years. As an event occurs, costs and QALYs are recorded 
and updated for each individual.
A health state transition model was used to develop 
NICE guidance for lipid modification treatment.1 The 
limitation of this approach is that it may be unable to 
capture the underlying heterogeneity in the population. 
Individual CVD risk can be estimated using CVD risk algo-
rithms such as QRISK2 that use a range of patient char-
acteristics such as age, sex, ethnicity, SBP and body mass 
index (BMI) to estimate a 10-year CVD risk.22 To capture 
this complexity in a health state transition model would 
require the construction of a large number of subgroups 
to reflect different subsets of patient characteristics and 
the variation in CVD risk in the population. This could 
become impractical to model. It also has the disadvantage 
that accuracy could be lost by using representative values 
for subgroups. An individual simulation model structure 
may be more appropriate to model the level of detail 
required to estimate CVD outcomes reflective of those in 
the population.
The Markovian memoryless property means that data 
on individual patients are not retained as they progress 
through the model. Accounting for individual patient 
history in a Markov model would require multiplying the 
number of health states to an infeasible level where the 
model would become too complex.
To accurately identify the effectiveness of each treat-
ment strategy in a population with or at high risk of CVD, 
an individual simulation model was deemed the most 
appropriate for the RUPEE (NHS) study to reflect the 
heterogeneity in the population, which impacts on the 
risk of a CVD event and subsequent costs and outcomes. 
The individual simulation model will use a discrete event 
approach to handle time.21
Model structure
The findings of the review were discussed with clinical 
experts to confirm the health events and the methods 
used to model the progression of persons through the 
disease pathway.
Model events (CVD, diabetes and adverse events)
The most commonly included types of CVD event in the 
reviewed models were CHD (angina and MI), cerebrovas-
cular events (transient ischaemic attack (TIA) and stroke) 
and PAD. It was decided that the CVD events relevant for 
the current model would reflect those most commonly 
included in prior such models. PAD will not be included 
as a CVD event in the model as there is less likely to be 
a definable acute PAD event compared with other CVD 
events such as MI and stroke. We will assume that patients 
can experience more than one CVD event in their life-
time. The risk of CVD will also be assumed to change with 
age in the model.
 o
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Table 1 Input paramaters
Model inputs Source
1. Individual dataset
  Population dataset Initial patient characteristics (see figure 2) for cohort of patients drawn from a representative 
national sample: HSE dataset 2011. The dataset will include patients who meet the entry criteria 
for the UMPIRE trial
2. Calculation of baseline risks
  Risk calculators
Risk of heart failure
Risk of first CVD event and onset of type 2 diabetes estimated for individuals using QRISK2 and 
QDiabetes.22 23
QRISK2: 10-year CVD risk (CVD outcomes defined as angina, MI, TIA and stroke)
QDiabetes: risk of acquiring type 2 diabetes over a 10-year period
Risks for subsequent CVD events estimated for individuals using the REACH algorithm.38
CVD outcomes defined as cardiovascular death (includes fatal stroke and MI), non-fatal MI, non-
fatal stroke and cardiovascular hospitalisation (includes hospitalisation for unstable angina and 
TIA)
Baseline risk per age using incidence rates in Cowie et al49
  Relative incidence of CVD events (TIA, 
stroke, angina, MI)
OXVASC cohort study: 91 106 individuals presenting with an acute vascular event in Oxfordshire, 
UK, in 2002–200541
3. Adherence to medication
  Probability of adherence to treatment with 
usual care
Estimates from HSE 2011 dataset on adherence to relevant drugs (statins, antihypertensives, 
aspirin)
  Relative risk of adherence: polypill versus 
usual care
Estimate the probability of adherence to≥ 2 antihypertensives, statin or antiplatelet for at 
least 4 days in the preceding week for polypill group versus usual care by applying a binomial 
regression to the UMPIRE dataset
4. Treatment effects of medication (antihypertensives, statin, antiplatelet)
  Relative risk of CVD with treatment versus 
no treatment
For base case analysis, conventional meta-analysis of ITT RCT data will be used from:
 ► Cholesterol Treatment Trialists' Collaboration50
 ► Blood Pressure Lowering Treatment Trialists' Collaboration28
 ► Antithrombotic Trialists' Collaboration
 ► Law, Morris and Wald51
Sensitivity analysis: test impact of adjusting for adherence within trials
5. Other treatment outcomes (beneficial events and adverse events) and mortality rates
  Adverse events
   Incident type 2 diabetes Relative risk of diabetes from statins/antihypertensives from meta-analyses of RCTs24–27
   GI bleeding Relative risk of bleeding resulting from aspirin using estimates from meta-analyses of RCTs28
   Cough Placebo-adjusted relative risk of cough resulting from ACE inhibitors using estimate from meta-
analyses of RCTs
   Reduction in heart failure Relative risk reduction in heart failure from antihypertensives33
Mortality
  Stroke case fatality (60 days)
Age<75
Age>75+
Estimate proportion of strokes that are fatal (with risks increasing with age). Estimate using the 
BHF Compendium of Health Statistics 2012, which has data from a record linkage study for 
England 2010
  MI case fatality (30 days)
   Age 30–54 Proportion of MIs that are fatal. Estimate using Oxford Record Linkage pill study.52 National-
population-based study, including all individuals admitted to hospital or who died suddenly from 
acute MI in 2010. Age was strongest predictive factor for 30-day case fatality
   Age 55–64
   Age 65–74
   Age 75–84
   Age 85+
  Death from other causes Estimated from national life tables (Office for National Statistics, England)42
6. Costs (medication, monitoring costs, health events)
  Drug costs (£ per year)
   Statins National Health Service (NHS) Electronic Drug Tariff44
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Diabetes is a risk factor for CVD with a substantial cost 
and impact on health-related quality of life; therefore, 
diabetes will be included as a comorbidity in the model. 
The risk of new onset diabetes will be estimated using the 
QDiabetes risk algorithm.23
Adverse effects from treatment will include an increase 
in the risk of new onset diabetes resulting from treat-
ment with statins and antihypertensive drugs.24–27 The 
risk of a persistent cough resulting from treatment with 
ACE inhibitors will be included as an event. The proba-
bility of a cough resulting from treatment will be sourced 
from meta-analyses of randomised controlled trial (RCT) 
data for ACE inhibitors. As aspirin use is associated with 
an increased risk of gastrointestinal bleeding,28 29 an 
increased risk of gastrointestinal bleeding from treatment 
with aspirin will be included.
Renal impairment will not be included in the model 
as an adverse effect of ACE inhibitors. While ACE inhib-
itors may cause an acute rise in serum creatinine in a 
few patients with renal artery stenosis and more gener-
ally cause a slight short-term increase in creatinine 
levels, the effects are complex and there may be a net 
improvement in renal function overall in a treated popu-
lation. The rate of falls and fractures will be estimated 
not to alter, given the evidence from randomised trials of 
blood-pressure-lowering agents, although this is an area 
of debate with regard to patients with higher levels of 
frailty.30 31
Other adverse effects from statin treatment such as liver 
dysfunction and myopathy will not be included in the 
model as severe cases are rare.1 32
Treatment with antihypertensives is associated with a 
reduction in heart failure; therefore, this will be included as 
an outcome in the model.33 Other outcomes of treatment 
are likely but will not be included, for example, a reduction 
in cancer with aspirin use of more than 5 years.34
Progression of individuals through model
The progression of persons through the disease pathway 
differs depending on the modelling approach: health 
state transition models such as the Markov model devel-
oped for NICE guidelines on lipid modification use a 
predefined transition matrix to determine progression 
through the CVD health states.35 Alternatively, simula-
tion models can use risk algorithms to estimate the prob-
ability of CVD events or new onset diabetes. The NICE 
guidelines for lipid modification recommend the use of 
QRISK2, which is a risk algorithm derived to estimate 
primary CVD risk in UK populations.1 22 The QRISK2 
risk algorithm predicts the risk of a 10-year CHD event 
Model inputs Source
   Aspirin
   Polypill Assumed to be aggregate cost of each drug in the combined pill
  Yearly monitoring costs while on 
medication
Primary care nurse (£ per hour)




Costs of health states and adverse events
Use NICE Quality Outcomes Framework to identify recommended management while on 
treatment (statins, antihypertensives, antiplatelet). A cost for stopping medication will also be 
applied (eg, two GP visits, tests as recommended in NICE clinical guideline 181)1









NICE lipids guideline 1811
   GI bleeding
   Cough (from ACE inhibitor use) NICE Hypertension guidelines 12743










Derived from HSE dataset
AHT, antihypertensive; CVD, cardiovascular disease; GP, general practitioner; HSE, Health Survey for England; ITT, Intention to treat; MI, 
myocardial infarction; NICE, National Institute for Health and Care Excellence; RCT, randomised controlled trial; TIA, transient ischaemic 
attack; UMPIRE, Use of a Multidrug Pill in Reducing cardiovascular Events.
Table 1 Continued 
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(angina, MI) or a cerebrovascular event (TIA, stroke). It 
does not include the risk of PAD. An alternative CVD risk 
algorithm is the Framingham equation;36 however, a vali-
dation study comparing QRISK2 and Framingham found 
that QRISK2 is better calibrated to a UK population.37 
The RUPEE (NHS) model will therefore use the QRISK2 
risk algorithm.
ruPee (nhs) eConoMIC MoDel
Figure 2 depicts the flowchart of the RUPEE (NHS) 
model structure. The oval shapes represent data inputs 
to the model, whereas the rectangular shapes represent 
processes.
Model description
In the RUPEE (NHS) model, costs and QALYs are 
recorded for each individual and an average cost and 
QALY for the simulated population are estimated. The 
RUPEE (NHS) model will be run twice, once to simulate 
costs and QALYs under usual care and once to simulate 
costs and QALYs under the polypill scenario (polypill 
scenario will include polypill version 1 and version 2). 
Individuals representing the UMPIRE trial inclusion 
Figure 2 Flowchart of RUPEE (NHS) model structure. AHT, antihypertensive; BMI, body mass index; CVD, cardiovascular 
disease; GI, gastrointestinal; HDL, high-density lipoprotein; HSE, Health Survey for England; QALY, quality-adjusted life year; 
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criteria will enter the model (label 1 in figure 2), and their 
baseline risk of a CVD event and new onset diabetes will 
be estimated using the QRISK2 CVD risk algorithm and 
QDiabetes algorithm (label 2 in figure 2), respectively. 
For each individual, whether or not they are adherent to 
medication will be simulated using Monte Carlo simula-
tion based on the probability of adherence in usual care 
(label 3a in figure 2). If the individual is simulated to be 
adherent to medication, their risk of a CVD event will 
be modified by a treatment effect (label 4 in figure 2). 
In the polypill scenario of the model, the probability of 
adherence will be further modified by the relative risk 
of adherence to medication. The relative risk of adher-
ence to medication will be sourced from the UMPIRE 
trial data (label 3b in figure 2). Individuals may expe-
rience a CVD event or onset of diabetes based on their 
estimated CVD and diabetes risk, which will be estimated 
using the QRISK2 and QDiabetes algorithms. Individuals 
may also experience an adverse reaction to medication (if 
adherent) including gastrointestinal bleeding, early onset 
of diabetes and a persistent cough. Costs and QALYs will 
be recorded for each event (including adverse events). 
Individuals can experience more than one event (model 
run for lifetime horizon), and patient characteristics such 
as age and history of previous events, such as a stroke or 
new onset diabetes, are updated during the model run, 
with an ensuing reflective increase in the risk of an event.
Input parameters
Each point in the flowchart is labelled, and a description of 
the process or data requirement label is described below. 
Table 1 provides further details on data input parameters 
for the RUPEE-NHS model and potential sources of data.
Population dataset
We will use the 2011 Health Survey for England (HSE) as 
a population dataset for the economic model. The HSE 
is a cross-sectional survey that contains anonymised infor-
mation on a representative sample of the population. 
The 2011 HSE dataset collected information on CVD, 
including individual CVD events and medication history. 
The dataset also contains information on demographic 
and socio-economic characteristics and health-related 
data such as BMI, SBP and LDL-C and history of CVD 
events. These data are required in order to estimate indi-
vidual baseline risks of CVD and diabetes in the model.
Calculation of baseline risks of events without treatment
Baseline risks for CVD for each sampled individual will 
be calculated using published risk algorithms. As per 
recent NICE guidance for lipid modification, we will use 
the recommended algorithm for CVD risk, QRISK2.1 22 
The algorithm was derived using QRESEARCH, a large 
database derived from the pseudonymised health records 
of over 13 million patients registered with a GP in the UK. 
If an individual has established CVD (previously experi-
enced a CVD event), we will estimate a secondary CVD 
risk using the REACH algorithm.38 A baseline risk for the 
onset of diabetes will be estimated using the QDiabetes 
algorithm.23
Simulating adherence to treatment under usual care
The RUPEE study will evaluate the effect of adherence 
to medication on long-term costs and health outcomes 
measured using QALYs. The average rates of adherence 
in clinical trials can be higher than in actual practice4 
as seen in the UMPIRE clinical trial population, which 
had an atypically high baseline adherence rate. Instead, 
adherence rates to medication (antihypertensives, statins 
and aspirin) under a usual care setting will be sourced 
from the 2011 HSE dataset. Participants in the 2011 HSE 
self-reported all the prescribed medications they had 
taken in the last 7 days. This was coded in the HSE dataset 
using the British National Formulary classifications codes. 
Using these data, we are able to identify the medication 
patients were prescribed and identify whether or not they 
were taking the prescribed medication in the last week. 
This will reflect adherence to medication in a usual care 
population. The data will be used to estimate the prob-
ability of each person being adherent or not to medica-
tion. Individual characteristics will be used as predictors 
of adherence; the characteristics will be chosen by refer-
ring to studies that have assessed predictors of adherence 
in persons taking treatment for CVD.39 40 A generalised 
linear mixed regression model will be used to estimate 
the probability of adherence to medication for each indi-
vidual. The probability of persistence with medication 
will not be assumed to be constant, and the model will 
include a probability of ceasing medication over time. 
The probability of medication cessation will be sourced 
from published literature on adherence.
Estimate relative risks of adherence to medication
We will estimate the relative risks of adherence to medica-
tion, using a generalised linear mixed regression model, 
which will be applied to the UMPIRE trial dataset (UK 
dataset). In the polypill scenario in the model, the prob-
ability of being adherent to medication will be further 
modified by the relative risks.
Adjust risk of events for treatment
We will source data on the treatment effects of statins, 
antihypertensives and aspirin from meta-analyses of 
intention-to-treat (ITT) RCTs. ITT analyses account for 
non-adherence in their findings and therefore underesti-
mate the impact of treatment on event risk. To overcome 
this, we will carry out sensitivity analyses to test the impact 
of adjusting for adherence within the trial. The risk of a 
CVD event will be adjusted by the relative risk of treat-
ment with statins, antihypertensives and aspirin, based on 
the medication(s) the person is taking and whether or 
not they are adherent to medication.
Simulation of events
Individuals in the model can experience a CVD event 
at a rate governed by their calculated baseline risk 
(estimated by the QRISK2 or REACH algorithms) and 
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adjusted for treatment effects if they have been simulated 
as adherent to treatment. CVD events will be categorised 
as a TIA, stroke, MI or angina. The relative incidence 
of each CVD event will be determined using published 
incidence data.41 Similarly, the risk of new onset diabetes 
will be calculated using the QDiabetes algorithm. We 
will simulate the incidence of adverse events as a result 
of treatment: new onset diabetes and gastrointestinal 
bleeds. Data on the probability of an adverse event will 
be sourced from meta-analyses of RCTs for the relevant 
drugs. Mortality risk will be modelled as mortality from 
stroke and MI and other cause of mortality. Data on other 
cause mortality will be estimated using national life tables 
for England and Wales.42
Assign cost and quality of life values
Costs and QALYs associated with each individual’s simu-
lated lifetime profile of CVD and related care will be 
estimated. Costs and QALYs will accrue for each person 
to reflect events, such as a stroke or new onset diabetes. 
Costs and utility values for health events will be sourced 
from published studies including the NICE guidelines 
for lipid modification and hypertension.1 35 43 Costs of 
medication will be sourced from the NHS National Drug 
Tariff.44
Change in age, treatment, CVD status and type 2 diabetes status
The simulation model will run for each individual for life-
time duration (death or maximum age of 100 years), and 
patient characteristics will be updated after each event 
or every 10 years (depending on which occurs first). A 
10-year update is used as the QRISK2 algorithm returns a 
10-year CVD risk.
Analysis
The simulation model will run for a sufficient number 
of iterations to provide stable results. Uncertainty in the 
model parameters will be examined using a probabilistic 
sensitivity analysis (PSA), which will reflect uncertainty 
over the values of the model inputs. Non-parametric boot-
strapping of HSE data will be carried out to examine the 
uncertainty related to the sampling. For each PSA itera-
tion, one non-parametric bootstrap sample will be drawn 
from the HSE dataset (by random sample with replace-
ment of individuals in the dataset). An incremental anal-
ysis will be conducted and incremental cost-effectiveness 
ratios and net benefit statistics will be estimated. We will 
also carry out a number of sensitivity analyses to test the 
impact of varying uncertain parameters in the model. 
This will include an analysis testing the impact of varying 
the polypill cost.
Validation
The model will be internally and externally validated. A 
checklist produced by the RUPEE steering group based 
on current published guidelines for checking models will 
be used, to ensure that the programmed model behaves 
as expected according to the theoretical model.21 45 The 
checklist includes tips for model developers, for example, 
on the use of sensitivity analyses to test that the model 
is operating correctly, and reprogramming complicated 
sections of code in another language. The model will also 
be reviewed and tested by an experienced modeller. The 
model results will be compared with real-world observa-
tions or the results of other models.
Dissemination of results
The findings of the economic evaluation will be presented 
to scientific and healthcare policy audiences in open-ac-
cess journals and at national and international confer-
ences. We will also present findings to NHS policy makers 
and pharmaceutical companies.
DIsCussIon
Medication adherence is important for disease manage-
ment, and benefits of increased adherence to preven-
tative medication for CVD include improved clinical 
outcomes.5 The UMPIRE clinical trial was conducted to 
evaluate the effect of a polypill strategy compared with 
usual care on adherence. It showed that the polypill 
strategy significantly augmented adherence, and this was 
reflected by improvements in SBP and LDL-C.8 Whether 
or not this impact remains in the long term cannot be 
determined from the trial data alone. The RUPEE (NHS) 
study is being conducted to evaluate the long-term impact 
of a polypill strategy; in particular, the analysis will eval-
uate the long-term impact of increased adherence on 
outcomes. An economic model is being developed to 
estimate the long-term costs and QALYs associated with 
implementing a polypill strategy in the NHS compared 
with usual care. This analysis will represent the first 
comprehensive cost effectiveness analysis using directly 
applicable clinical trial data.
This paper outlines the process behind the design 
of the economic model. We carried out a review of 
published CVD models to identify a modelling approach 
that would suit the healthcare decision: use of a polypill 
versus usual care in a population with or at high risk of 
CVD. We identified an individual simulation model as the 
most appropriate approach as it allows the heterogeneity 
in the population to be adequately reflected. The model 
will use validated disease risk algorithms to estimate the 
probability of an individual experiencing a CVD event or 
the onset of diabetes. Individuals can also experience an 
increased risk of an adverse event (diabetes, cough and 
gastrointestinal bleeding) from treatment. The risk of a 
CVD event will be reduced if the individual is adherent to 
treatment. We will simulate adherence to treatment using 
data from the HSE 2011 dataset. The probability of adher-
ence in the polypill scenario will be further modified by 
the relative risks of adherence to medication, which will 
be sourced from the UMPIRE trial data for the English 
population. Costs and QALYs will be estimated for each 
individual and aggregated across the sample population 
(based on the HSE 2011 dataset).
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The RUPEE (NHS) model will have a number of 
advantages over existing models constructed to evaluate 
a CVD polypill.46–48 One advantage is the use of an indi-
vidual simulation model, which will allow us to capture 
the heterogeneity in the variation in CVD risk in the UK 
population unlike other models that use Markov-type 
transition state models. Another is that we will extrapo-
late data on adherence to medication from a nationally 
representative population dataset (HSE), which will 
allow us to simulate adherence per individual rather than 
assuming a constant adherence across our population. 
We will also allow for adverse events from treatment and 
treatment cessation, therefore more accurately reflecting 
clinical practice.
It would be preferable to use per protocol treatment 
effectiveness data in our analysis as ITT data already 
account for adherence (people switching and ceasing 
medication during the trial period). However, per 
protocol data are difficult to obtain for all drugs; there-
fore, we will use the ITT treatment effect data and carry 
out sensitivity analyses to test the impact.
The introduction of a CVD preventive polypill strategy 
will simplify pill taking for patients, potentially leading to 
greater adherence and better health outcomes. This anal-
ysis will provide information on the cost-effectiveness of 
the polypill in an NHS setting.
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